This application for renewal of the University of Virginia Cancer Center Support Grant builds on its original strengths in basic science research. However, it has been substantially re-structured to enhance the cohesiveness and cancer focus of the individual Programs and to facilitate meaningful interactions between laboratory and clinical scientists. The Cancer Center Support Grant has been organized into five Programs: Program 1, Cell Signaling focuses on molecular mechanisms of intracellular regulation including oncogenes, receptors, intracellular signal transduction, gene regulation and DNA replication, which are key to understanding normal and malignant growth. Program 2, Endocrinology focuses on growth, differentiation and regulation of endocrine cells, particularly of the pituitary, thyroid and gonads. This Program has a distinguished record of clinical, translational and fundamental research. Program 3, Immunology has great strengths in the areas of immune cell activation, antigen presentation/recognition and auto-immunity, issues which are of fundamental and practical importance in cancer immunology. Program 4, Metastasis, Invasion and Cell Surfaces is a new Program, built on existing basic science strengths in membranes, extracellular matrices and proteases, which will be brought to bear on the important problems of tumor invasion and metastasis. Program 5, Clinical Oncology is a new Program designed to provide the clinical venue for interactions with the four laboratory-based Programs. Its goal is to identify cellular or immunologic targets for therapy or diagnosis; develop drugs or biologicals to attack that target; and test these drugs or biologicals in the clinical setting. Inter-disciplinary working groups with individuals drawn from each stage of the development process are being established to facilitate this process. In addition to the Programmatic re-structuring, the Cancer Center has consolidated its inpatient and ambulatory cancer care facilities, established a centralized clinical trials protocol review and monitoring system, coordinated oncology research programs with existing areas of related research strength and initiated the recruitment of clinical and translational oncology researchers. The net result of these changes is expected to be a system which enhances understanding of cancer and facilitates scientific improvements in cancer treatment, diagnosis and prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-14
Application #
6533121
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1987-07-01
Project End
2004-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
14
Fiscal Year
2002
Total Cost
$1,943,288
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148

Showing the most recent 10 out of 539 publications